Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win Read more
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod Read more
Regeneron ends eye disease trial for anti-CD3 antibody following safety review Read more
February 12, 2025 @ 6:00 pm

Attendees will have the opportunity to engage with the Cancer Research Horizons Ventures team, a dedicated group of experts specialising in identifying and nurturing high-potential, oncology-focused ventures. This team plays a critical role in accelerating the development of early-stage biotech start-ups by providing not only funding but also strategic guidance and industry connections.
By working closely with visionary entrepreneurs, they aim to drive innovation in cancer treatment and technologies. In addition to managing the Cancer Research Horizons Seed Fund, they also support portfolio companies in areas such as business development, licensing, and commercialisation, ensuring these start-ups have the tools and resources to bring their groundbreaking solutions to market. This is an invaluable opportunity to connect with professionals at the forefront of cancer innovation, gain insights into the venture funding process, and explore potential partnerships that could shape the future of oncology.